 | • レポートコード：MRC2-11QY08805 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はPEG化医薬品のグローバル市場について調査・分析したレポートです。種類別（リンカー、クロスリンカー、その他）市場規模、用途別（がん、慢性腎臓病、肝炎、多発性硬化症、血友病、胃腸障害）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別PEG化医薬品の競争状況、市場シェア ・世界のPEG化医薬品市場：種類別市場規模 2015年-2020年（リンカー、クロスリンカー、その他） ・世界のPEG化医薬品市場：種類別市場規模予測 2021年-2026年（リンカー、クロスリンカー、その他） ・世界のPEG化医薬品市場：用途別市場規模 2015年-2020年（がん、慢性腎臓病、肝炎、多発性硬化症、血友病、胃腸障害） ・世界のPEG化医薬品市場：用途別市場規模予測 2021年-2026年（がん、慢性腎臓病、肝炎、多発性硬化症、血友病、胃腸障害） ・北米のPEG化医薬品市場分析：米国、カナダ ・ヨーロッパのPEG化医薬品市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのPEG化医薬品市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のPEG化医薬品市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのPEG化医薬品市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Thermo Fisher Scientific、Merck、Johnson & Johnson、Creative PEGworks、NOF、Quanta BioDesign Celares Biomatrik、Iris Biotech Laysan Bio ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global PEGylated Drugs Market
The global PEGylated Drugs market size is projected to reach US$ 7218.2 million by 2026, from US$ 7003.6 million in 2020, at a CAGR of 2.8%% during 2021-2026.
Global PEGylated Drugs Scope and Market Size
PEGylated Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global PEGylated Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the PEGylated Drugs market is segmented into
Linkers
Cross-Linkers
Other
Segment by Application, the PEGylated Drugs market is segmented into
Cancer
Chronic Kidney Diseases
Hepatitis
Multiple Sclerosis
Hemophilia
Gastrointestinal Disorders
Regional and Country-level Analysis
The PEGylated Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the PEGylated Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and PEGylated Drugs Market Share Analysis
PEGylated Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in PEGylated Drugs business, the date to enter into the PEGylated Drugs market, PEGylated Drugs product introduction, recent developments, etc.
The major vendors covered:
Thermo Fisher Scientific
Merck
Johnson & Johnson
Creative PEGworks
NOF
Quanta BioDesign Celares Biomatrik
Iris Biotech Laysan Bio
…
1 Study Coverage
1.1 PEGylated Drugs Product Introduction
1.2 Market Segments
1.3 Key PEGylated Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global PEGylated Drugs Market Size Growth Rate by Type
1.4.2 Linkers
1.4.3 Cross-Linkers
1.4.4 Other
1.5 Market by Application
1.5.1 Global PEGylated Drugs Market Size Growth Rate by Application
1.5.2 Cancer
1.5.3 Chronic Kidney Diseases
1.5.4 Hepatitis
1.5.5 Multiple Sclerosis
1.5.6 Hemophilia
1.5.7 Gastrointestinal Disorders
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global PEGylated Drugs Market Size, Estimates and Forecasts
2.1.1 Global PEGylated Drugs Revenue 2015-2026
2.1.2 Global PEGylated Drugs Sales 2015-2026
2.2 Global PEGylated Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global PEGylated Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global PEGylated Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global PEGylated Drugs Competitor Landscape by Players
3.1 PEGylated Drugs Sales by Manufacturers
3.1.1 PEGylated Drugs Sales by Manufacturers (2015-2020)
3.1.2 PEGylated Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 PEGylated Drugs Revenue by Manufacturers
3.2.1 PEGylated Drugs Revenue by Manufacturers (2015-2020)
3.2.2 PEGylated Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global PEGylated Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by PEGylated Drugs Revenue in 2019
3.2.5 Global PEGylated Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 PEGylated Drugs Price by Manufacturers
3.4 PEGylated Drugs Manufacturing Base Distribution, Product Types
3.4.1 PEGylated Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers PEGylated Drugs Product Type
3.4.3 Date of International Manufacturers Enter into PEGylated Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global PEGylated Drugs Market Size by Type (2015-2020)
4.1.1 Global PEGylated Drugs Sales by Type (2015-2020)
4.1.2 Global PEGylated Drugs Revenue by Type (2015-2020)
4.1.3 PEGylated Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global PEGylated Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global PEGylated Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global PEGylated Drugs Revenue Forecast by Type (2021-2026)
4.2.3 PEGylated Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global PEGylated Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global PEGylated Drugs Market Size by Application (2015-2020)
5.1.1 Global PEGylated Drugs Sales by Application (2015-2020)
5.1.2 Global PEGylated Drugs Revenue by Application (2015-2020)
5.1.3 PEGylated Drugs Price by Application (2015-2020)
5.2 PEGylated Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global PEGylated Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global PEGylated Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global PEGylated Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America PEGylated Drugs by Country
6.1.1 North America PEGylated Drugs Sales by Country
6.1.2 North America PEGylated Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America PEGylated Drugs Market Facts & Figures by Type
6.3 North America PEGylated Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe PEGylated Drugs by Country
7.1.1 Europe PEGylated Drugs Sales by Country
7.1.2 Europe PEGylated Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe PEGylated Drugs Market Facts & Figures by Type
7.3 Europe PEGylated Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific PEGylated Drugs by Region
8.1.1 Asia Pacific PEGylated Drugs Sales by Region
8.1.2 Asia Pacific PEGylated Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific PEGylated Drugs Market Facts & Figures by Type
8.3 Asia Pacific PEGylated Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America PEGylated Drugs by Country
9.1.1 Latin America PEGylated Drugs Sales by Country
9.1.2 Latin America PEGylated Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America PEGylated Drugs Market Facts & Figures by Type
9.3 Central & South America PEGylated Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa PEGylated Drugs by Country
10.1.1 Middle East and Africa PEGylated Drugs Sales by Country
10.1.2 Middle East and Africa PEGylated Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa PEGylated Drugs Market Facts & Figures by Type
10.3 Middle East and Africa PEGylated Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Corporation Information
11.1.2 Thermo Fisher Scientific Description and Business Overview
11.1.3 Thermo Fisher Scientific Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Thermo Fisher Scientific PEGylated Drugs Products Offered
11.1.5 Thermo Fisher Scientific Related Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Description and Business Overview
11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Merck PEGylated Drugs Products Offered
11.2.5 Merck Related Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Description and Business Overview
11.3.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Johnson & Johnson PEGylated Drugs Products Offered
11.3.5 Johnson & Johnson Related Developments
11.4 Creative PEGworks
11.4.1 Creative PEGworks Corporation Information
11.4.2 Creative PEGworks Description and Business Overview
11.4.3 Creative PEGworks Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Creative PEGworks PEGylated Drugs Products Offered
11.4.5 Creative PEGworks Related Developments
11.5 NOF
11.5.1 NOF Corporation Information
11.5.2 NOF Description and Business Overview
11.5.3 NOF Sales, Revenue and Gross Margin (2015-2020)
11.5.4 NOF PEGylated Drugs Products Offered
11.5.5 NOF Related Developments
11.6 Quanta BioDesign Celares Biomatrik
11.6.1 Quanta BioDesign Celares Biomatrik Corporation Information
11.6.2 Quanta BioDesign Celares Biomatrik Description and Business Overview
11.6.3 Quanta BioDesign Celares Biomatrik Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Quanta BioDesign Celares Biomatrik PEGylated Drugs Products Offered
11.6.5 Quanta BioDesign Celares Biomatrik Related Developments
11.7 Iris Biotech Laysan Bio
11.7.1 Iris Biotech Laysan Bio Corporation Information
11.7.2 Iris Biotech Laysan Bio Description and Business Overview
11.7.3 Iris Biotech Laysan Bio Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Iris Biotech Laysan Bio PEGylated Drugs Products Offered
11.7.5 Iris Biotech Laysan Bio Related Developments
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Corporation Information
11.1.2 Thermo Fisher Scientific Description and Business Overview
11.1.3 Thermo Fisher Scientific Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Thermo Fisher Scientific PEGylated Drugs Products Offered
11.1.5 Thermo Fisher Scientific Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 PEGylated Drugs Market Estimates and Projections by Region
12.1.1 Global PEGylated Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global PEGylated Drugs Revenue Forecast by Regions 2021-2026
12.2 North America PEGylated Drugs Market Size Forecast (2021-2026)
12.2.1 North America: PEGylated Drugs Sales Forecast (2021-2026)
12.2.2 North America: PEGylated Drugs Revenue Forecast (2021-2026)
12.2.3 North America: PEGylated Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe PEGylated Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: PEGylated Drugs Sales Forecast (2021-2026)
12.3.2 Europe: PEGylated Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: PEGylated Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific PEGylated Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: PEGylated Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: PEGylated Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: PEGylated Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America PEGylated Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: PEGylated Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: PEGylated Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: PEGylated Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa PEGylated Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: PEGylated Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: PEGylated Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: PEGylated Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key PEGylated Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 PEGylated Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. PEGylated Drugs Market Segments
Table 2. Ranking of Global Top PEGylated Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global PEGylated Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Linkers
Table 5. Major Manufacturers of Cross-Linkers
Table 6. Major Manufacturers of Other
Table 7. Global PEGylated Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global PEGylated Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global PEGylated Drugs Sales by Regions 2015-2020 (K Units)
Table 10. Global PEGylated Drugs Sales Market Share by Regions (2015-2020)
Table 11. Global PEGylated Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global PEGylated Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 13. Global PEGylated Drugs Sales Share by Manufacturers (2015-2020)
Table 14. Global PEGylated Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global PEGylated Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PEGylated Drugs as of 2019)
Table 16. PEGylated Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. PEGylated Drugs Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers PEGylated Drugs Price (2015-2020) (USD/Unit)
Table 19. PEGylated Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers PEGylated Drugs Product Type
Table 21. Date of International Manufacturers Enter into PEGylated Drugs Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global PEGylated Drugs Sales by Type (2015-2020) (K Units)
Table 24. Global PEGylated Drugs Sales Share by Type (2015-2020)
Table 25. Global PEGylated Drugs Revenue by Type (2015-2020) (US$ Million)
Table 26. Global PEGylated Drugs Revenue Share by Type (2015-2020)
Table 27. PEGylated Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 28. Global PEGylated Drugs Sales by Application (2015-2020) (K Units)
Table 29. Global PEGylated Drugs Sales Share by Application (2015-2020)
Table 30. North America PEGylated Drugs Sales by Country (2015-2020) (K Units)
Table 31. North America PEGylated Drugs Sales Market Share by Country (2015-2020)
Table 32. North America PEGylated Drugs Revenue by Country (2015-2020) (US$ Million)
Table 33. North America PEGylated Drugs Revenue Market Share by Country (2015-2020)
Table 34. North America PEGylated Drugs Sales by Type (2015-2020) (K Units)
Table 35. North America PEGylated Drugs Sales Market Share by Type (2015-2020)
Table 36. North America PEGylated Drugs Sales by Application (2015-2020) (K Units)
Table 37. North America PEGylated Drugs Sales Market Share by Application (2015-2020)
Table 38. Europe PEGylated Drugs Sales by Country (2015-2020) (K Units)
Table 39. Europe PEGylated Drugs Sales Market Share by Country (2015-2020)
Table 40. Europe PEGylated Drugs Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe PEGylated Drugs Revenue Market Share by Country (2015-2020)
Table 42. Europe PEGylated Drugs Sales by Type (2015-2020) (K Units)
Table 43. Europe PEGylated Drugs Sales Market Share by Type (2015-2020)
Table 44. Europe PEGylated Drugs Sales by Application (2015-2020) (K Units)
Table 45. Europe PEGylated Drugs Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific PEGylated Drugs Sales by Region (2015-2020) (K Units)
Table 47. Asia Pacific PEGylated Drugs Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific PEGylated Drugs Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific PEGylated Drugs Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific PEGylated Drugs Sales by Type (2015-2020) (K Units)
Table 51. Asia Pacific PEGylated Drugs Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific PEGylated Drugs Sales by Application (2015-2020) (K Units)
Table 53. Asia Pacific PEGylated Drugs Sales Market Share by Application (2015-2020)
Table 54. Latin America PEGylated Drugs Sales by Country (2015-2020) (K Units)
Table 55. Latin America PEGylated Drugs Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa PEGylated Drugs Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America PEGylated Drugs Revenue Market Share by Country (2015-2020)
Table 58. Latin America PEGylated Drugs Sales by Type (2015-2020) (K Units)
Table 59. Latin America PEGylated Drugs Sales Market Share by Type (2015-2020)
Table 60. Latin America PEGylated Drugs Sales by Application (2015-2020) (K Units)
Table 61. Latin America PEGylated Drugs Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa PEGylated Drugs Sales by Country (2015-2020) (K Units)
Table 63. Middle East and Africa PEGylated Drugs Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa PEGylated Drugs Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa PEGylated Drugs Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa PEGylated Drugs Sales by Type (2015-2020) (K Units)
Table 67. Middle East and Africa PEGylated Drugs Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa PEGylated Drugs Sales by Application (2015-2020) (K Units)
Table 69. Middle East and Africa PEGylated Drugs Sales Market Share by Application (2015-2020)
Table 70. Thermo Fisher Scientific Corporation Information
Table 71. Thermo Fisher Scientific Description and Major Businesses
Table 72. Thermo Fisher Scientific PEGylated Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 73. Thermo Fisher Scientific Product
Table 74. Thermo Fisher Scientific Recent Development
Table 75. Merck Corporation Information
Table 76. Merck Description and Major Businesses
Table 77. Merck PEGylated Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Merck Product
Table 79. Merck Recent Development
Table 80. Johnson & Johnson Corporation Information
Table 81. Johnson & Johnson Description and Major Businesses
Table 82. Johnson & Johnson PEGylated Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Johnson & Johnson Product
Table 84. Johnson & Johnson Recent Development
Table 85. Creative PEGworks Corporation Information
Table 86. Creative PEGworks Description and Major Businesses
Table 87. Creative PEGworks PEGylated Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Creative PEGworks Product
Table 89. Creative PEGworks Recent Development
Table 90. NOF Corporation Information
Table 91. NOF Description and Major Businesses
Table 92. NOF PEGylated Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. NOF Product
Table 94. NOF Recent Development
Table 95. Quanta BioDesign Celares Biomatrik Corporation Information
Table 96. Quanta BioDesign Celares Biomatrik Description and Major Businesses
Table 97. Quanta BioDesign Celares Biomatrik PEGylated Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Quanta BioDesign Celares Biomatrik Product
Table 99. Quanta BioDesign Celares Biomatrik Recent Development
Table 100. Iris Biotech Laysan Bio Corporation Information
Table 101. Iris Biotech Laysan Bio Description and Major Businesses
Table 102. Iris Biotech Laysan Bio PEGylated Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Iris Biotech Laysan Bio Product
Table 104. Iris Biotech Laysan Bio Recent Development
Table 105. Global PEGylated Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 106. Global PEGylated Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 107. Global PEGylated Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 108. Global PEGylated Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 109. North America: PEGylated Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 110. North America: PEGylated Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Europe: PEGylated Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 112. Europe: PEGylated Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 113. Asia Pacific: PEGylated Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 114. Asia Pacific: PEGylated Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 115. Latin America: PEGylated Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 116. Latin America: PEGylated Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 117. Middle East and Africa: PEGylated Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 118. Middle East and Africa: PEGylated Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 119. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 120. Key Challenges
Table 121. Market Risks
Table 122. Main Points Interviewed from Key PEGylated Drugs Players
Table 123. PEGylated Drugs Customers List
Table 124. PEGylated Drugs Distributors List
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. PEGylated Drugs Product Picture
Figure 2. Global PEGylated Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Linkers Product Picture
Figure 4. Cross-Linkers Product Picture
Figure 5. Other Product Picture
Figure 6. Global PEGylated Drugs Sales Market Share by Application in 2020 & 2026
Figure 7. Cancer
Figure 8. Chronic Kidney Diseases
Figure 9. Hepatitis
Figure 10. Multiple Sclerosis
Figure 11. Hemophilia
Figure 12. Gastrointestinal Disorders
Figure 13. PEGylated Drugs Report Years Considered
Figure 14. Global PEGylated Drugs Market Size 2015-2026 (US$ Million)
Figure 15. Global PEGylated Drugs Sales 2015-2026 (K Units)
Figure 16. Global PEGylated Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global PEGylated Drugs Sales Market Share by Region (2015-2020)
Figure 18. Global PEGylated Drugs Sales Market Share by Region in 2019
Figure 19. Global PEGylated Drugs Revenue Market Share by Region (2015-2020)
Figure 20. Global PEGylated Drugs Revenue Market Share by Region in 2019
Figure 21. Global PEGylated Drugs Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by PEGylated Drugs Revenue in 2019
Figure 23. PEGylated Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global PEGylated Drugs Sales Market Share by Type (2015-2020)
Figure 25. Global PEGylated Drugs Sales Market Share by Type in 2019
Figure 26. Global PEGylated Drugs Revenue Market Share by Type (2015-2020)
Figure 27. Global PEGylated Drugs Revenue Market Share by Type in 2019
Figure 28. Global PEGylated Drugs Market Share by Price Range (2015-2020)
Figure 29. Global PEGylated Drugs Sales Market Share by Application (2015-2020)
Figure 30. Global PEGylated Drugs Sales Market Share by Application in 2019
Figure 31. Global PEGylated Drugs Revenue Market Share by Application (2015-2020)
Figure 32. Global PEGylated Drugs Revenue Market Share by Application in 2019
Figure 33. North America PEGylated Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 34. North America PEGylated Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America PEGylated Drugs Sales Market Share by Country in 2019
Figure 36. North America PEGylated Drugs Revenue Market Share by Country in 2019
Figure 37. U.S. PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 38. U.S. PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 40. Canada PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America PEGylated Drugs Market Share by Type in 2019
Figure 42. North America PEGylated Drugs Market Share by Application in 2019
Figure 43. Europe PEGylated Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 44. Europe PEGylated Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe PEGylated Drugs Sales Market Share by Country in 2019
Figure 46. Europe PEGylated Drugs Revenue Market Share by Country in 2019
Figure 47. Germany PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 48. Germany PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 50. France PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. U.K. PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. Italy PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 56. Russia PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe PEGylated Drugs Market Share by Type in 2019
Figure 58. Europe PEGylated Drugs Market Share by Application in 2019
Figure 59. Asia Pacific PEGylated Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 60. Asia Pacific PEGylated Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific PEGylated Drugs Sales Market Share by Region in 2019
Figure 62. Asia Pacific PEGylated Drugs Revenue Market Share by Region in 2019
Figure 63. China PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 64. China PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. Japan PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. South Korea PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. India PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. Australia PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Taiwan PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Indonesia PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Thailand PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Malaysia PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Philippines PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 84. Vietnam PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific PEGylated Drugs Market Share by Type in 2019
Figure 86. Asia Pacific PEGylated Drugs Market Share by Application in 2019
Figure 87. Latin America PEGylated Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 88. Latin America PEGylated Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America PEGylated Drugs Sales Market Share by Country in 2019
Figure 90. Latin America PEGylated Drugs Revenue Market Share by Country in 2019
Figure 91. Mexico PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Mexico PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Brazil PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 96. Argentina PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America PEGylated Drugs Market Share by Type in 2019
Figure 98. Latin America PEGylated Drugs Market Share by Application in 2019
Figure 99. Middle East and Africa PEGylated Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 100. Middle East and Africa PEGylated Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa PEGylated Drugs Sales Market Share by Country in 2019
Figure 102. Middle East and Africa PEGylated Drugs Revenue Market Share by Country in 2019
Figure 103. Turkey PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. Turkey PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 106. Saudi Arabia PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E PEGylated Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 108. U.A.E PEGylated Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa PEGylated Drugs Market Share by Type in 2019
Figure 110. Middle East and Africa PEGylated Drugs Market Share by Application in 2019
Figure 111. North America PEGylated Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. North America PEGylated Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe PEGylated Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Europe PEGylated Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific PEGylated Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Asia Pacific PEGylated Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America PEGylated Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Latin America PEGylated Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa PEGylated Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 120. Middle East and Africa PEGylated Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
PEG化タンパク質治療薬の世界市場（～2026年） PEGylation is the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to molecules, such as a drug, therapeutic protein, or vesicle. PEGylated protein therapeutics is estimated to show significant market growth during the forecast period, majorly due to the, growth …- 腎臓/腎がん治療薬の世界市場（～2026年） Kidney/Renal Cancer Drugs are used to cure kidney cancers. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors bo…
- C型肝炎治療薬の世界市場（～2026年） Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc. Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepa…
- 筋萎縮性側索硬化症（ALS）治療薬の世界市場（～2026年） Amyotrophic lateral sclerosis is a neurodegenerative disease. ALS affects the nerve cells in the brain and spinal cord that control the voluntary muscles. It is also known as the Lou Gehrig’s disease. Amyotrophic lateral sclerosis can be caused due to various factors such as genetics or environmenta…
- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…